Price movement over the last 24 hours
ProShares Ultra Silver ETF vs Danaher Corporation — how do they compare? ProShares Ultra Silver ETF trades at $65.7, while Danaher Corporation trades at $191.25 (market cap $137.44B). The key difference: Danaher Corporation pays a 0.82% dividend while ProShares Ultra Silver ETF pays none, and Danaher Corporation is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | DHR | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $242.05 |
52-Week Low | $48.15 | $161.91 |
Market Cap | — | $137.44B |
Enterprise Value | — | $150.22B |
Dividend Yield | — | 0.82% |
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
Danaher (DHR) trades at $193.62, down 2.18% today but remains in a bullish technical trend with strong support near $190. The company demonstrates solid fundamentals with a 58.94% gross margin and consistent earnings beats in recent quarters. Recent news highlights strategic collaborations and a pending acquisition of Masimo, approved by shareholders in May 2026, signaling growth initiatives.
The outlook is positive with a consensus price target of $214.73, implying 11% upside. Key risks include revenue stagnation and a high P/E ratio of 37.52. Analyst sentiment is strongly bullish (69% buy ratings), but investors should monitor execution on acquisitions and bioprocessing demand trends for sustained momentum.
Trailing returns across standard periods
Latest headlines on both assets
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →